Literature DB >> 32820482

The Spectrum of Disease Severity in Cirrhosis and Its Implications for Hemostasis.

Matthew J Stotts1, Ton Lisman2,3, Nicolas M Intagliata1.   

Abstract

Bleeding and thrombosis are both common complications that patients with advanced liver disease experience. While hemostatic pathways remain largely intact with cirrhosis, this balance can quickly shift in the direction of bleeding or clotting in an unpredictable manner. A growing body of literature is attempting to shed light on difficult scenarios that clinicians often face, ranging from predicting and mitigating bleeding risk in those who need invasive procedures to determining the best strategies to manage both bleeding and thrombotic complications when they occur. Studies examining hemostasis in those with advanced liver disease, however, often include heterogeneous cohorts with varied methodology. While these studies often select a cohort of all types and degrees of cirrhosis, emerging evidence suggests significant differences in underlying systemic inflammation and hemostatic abnormalities among specific phenotypes of liver disease, ranging from compensated cirrhosis to decompensated cirrhosis and acute-on-chronic liver failure. It is paramount that future studies account for these differing disease severities if we hope to address the many critical knowledge gaps in this field. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32820482     DOI: 10.1055/s-0040-1715449

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  3 in total

1.  Blood products and liver transplantation: A strategy to balance optimal preparation with effective blood stewardship.

Authors:  Christopher J Little; Glen E Leverson; Laura L Hammel; Joseph P Connor; David P Al-Adra
Journal:  Transfusion       Date:  2022-08-20       Impact factor: 3.337

2.  Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates.

Authors:  Annabel Blasi; Vishal C Patel; Eva N H E Spanke; Jelle Adelmeijer; Marilena Stamouli; Ane Zamalloa; Eleanor Corcoran; Andrea Calvo; Javier Fernandez; William Bernal; Ton Lisman
Journal:  Liver Int       Date:  2021-12-20       Impact factor: 8.754

3.  Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism.

Authors:  Diego Martínez-Urbistondo; Rocío G de la Garza; Paula Villares-Fernández; Carme Font; Sebastian Schellong; Juan José López-Núñez; Aída Gil-Díaz; María Del Carmen Díaz-Pedroche; Jana Hirmerova; Manuel Monreal
Journal:  Intern Emerg Med       Date:  2021-10-09       Impact factor: 5.472

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.